No Data
Overview of the lifting of restrictions on the tradability of A-shares | February 24.
According to the Zhitong Finance App, on February 24, 20 listed companies had their restricted shares unlocked, with a total market value of approximately 10.741 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Stock Type Unlocked Shares Luzhou Laojiao 000568 Stock-based Incentive 2.051 million Xiamen Xinde Co Ltd. 000701 Stock-based Incentive 0.172 million Shanzi Gaoke 000981 Other 2.988 billion YANKUANG ENERGY 600188 Stock-based Incentive 29.2178 million Anhui Tongfeng Electronics 600237 Additional issuance of A shares allocated to legal persons 17.192 million Zhejiang Hisun Pharmaceutical 60
Zhejiang Hisun Pharmaceutical (600267.SH): The DeepSeek-R1 model has been integrated into HisunAI.
On February 14, Gelonghui reported that Zhejiang Hisun Pharmaceutical (600267.SH) stated on the investor interaction platform that the DeepSeek-R1 model has been integrated with Zhejiang Hisun Pharmaceutical's Hisun AI. The company's IT department will organize training to Share insights on DeepSeek interpretation and practical AI skills. Furthermore, the company highly recognizes the empowering potential of AI technology for future industrial development, and hopes to leverage strategic cooperation with AI pharmaceutical companies to facilitate breakthroughs in new drug research and development by overcoming technological barriers and advancing the application of AI in the drug development phase. On the other hand, the company is also striving to build a team by introducing high-level talents from the AI field.
Zhejiang Hisun Pharmaceutical (SHSE:600267) Adds CN¥448m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 38%
Haizheng Pharmaceutical: Zhejiang Haizheng Pharmaceutical Co., Ltd. 2024 Annual Results Pre-Profit Announcement
Zhejiang Haizheng Pharmaceutical Co., Ltd. 2024 Annual Results Pre-Profit Announcement
Zhejiang Hisun Pharmaceutical (600267.SH): Net profit is expected to be between 0.57 billion yuan and 0.63 billion yuan for 2024.
Gelonghui, January 22 │ Zhejiang Hisun Pharmaceutical (600267.SH) announced the preliminary earnings forecast for the year 2024. According to preliminary calculations by the financial department, it is expected that the net income attributable to shareholders of the listed company will be between 570 million yuan and 630 million yuan in 2024, marking a turnaround from losses to profits compared to the same period last year. It is anticipated that the net income attributable to shareholders of the listed company, after excluding non-recurring gains and losses, will be between 400 million yuan and 460 million yuan in 2024. During the reporting period, the company focused on marketing transformation and reform, overcoming the impact of factors such as product price reductions, resulting in good growth of its main products.
Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Stock's 27% Plummet
